evening Thank you, good Good and to Parag. everyone. morning
the As Prasad highlighted, We a sustained the been FY able have yet steady year, and it 'XX challenges being and been quite to a is to deliver rose performance. has fulfilling. challenging
to our the revisited strategy risk. have mitigate We and new opportunities to cater
environment. in creates strong opportunity an for Our of current financial strength the sheet business us to grow balance
net growth North strong markets, generics, market the across markets We revenue most and our across you One key regained major take highlights India in range the brands me progress our medical for journey. to digitalization Health, of sustainability made of than key $XXX Germany of in to Nimbus in with cannabis of significant collaboration and of market free exclusive a high-growth year. market. through America and Let steady flow the in in and is of $X surplus generation cash entered leading aspirational EBITDA of share Novartis of space in-licensing of ROCE more of markets, India targets, some growth acquisition billion million, in generics milestone improved our emerging branded strong business of
simultaneously making investments on strengthen focus pipeline to continue capabilities. we while to Additionally, and productivity, our
our and generic API will X. that to us for new near to as in we and and for Horizon is encouraged incremental creation opportunities drive is are of business the up such of of X, what continue core sized Horizon our long-term midterm, several call we While businesses business growth that the models scaling growth, small existing witness
Our businesses. X to Horizon invest allow and and X for financial both us Horizon grow strength
Now, as numbers let the local these respective well Please this to the as for through all section QX year are key me note the currencies. 'XX. of in you business full in that take references highlights
a strong of business Our [indiscernible] of on growth This new growth largely cost quarter X% sequential billion for recorded launches basis, we for a year-over-year recorded sales North year of was previous generics the $X.X X% On $XXX the and [ph] years. XX% over with product by business. led million key sales of a full injection. with America vasopressin
during for the products which helped three impact new to We grow to quarter our XX and launched share existing year. products of We products erosion. mitigate market partially during able price the overall of the are many also the to
launch improve 'XX. expect momentum further to in FY the We
quarter this with of a product Europe driven were EURXX launches. sequential EURXXX recorded and grown basis, On XX% and growth sales million strong a has business new of year-on-year Our by quarter the sales growth year of XX%. million by X%, full
Germany, launched U.K. in quarter, each four the X and Spain each two we and and products in Italy products During France. in
year, our markets full the Europe. During new we across launches XX had in
'XX. FY We in momentum expect this strong to continue
sales year-on-year products and recorded XX%. business markets emerging INRX,XXX We of growth emerging X%. a XX launched by emerging market new On products of a grew crores during during and markets. quarter XX% been of across basis, a of Our sequential quarter sales year countries XX the new and year various with growth INRX,XXX the full the has
market business by emerging currency. segment, rates. by In partially performance fluctuation by basis strong four stocking on the a higher Ukraine in constant and in we XX% currency. in business in situation quarter. Russia the and business Russia raised coming grew on XX% federal constant basis expect currency uncertainty during Within normalize war FY led income was significant the year-to-year a and [indiscernible] which quarter account current XX% in QX in quarter-to-quarter the This up grew on of divestment Russia The Russia and sales to a 'XX, of
the managed with have operation situation the term business continued financially We the and effective our of ensured safety and very securing hedging. well the near employees,
a of sales recorded sales X%. of sequential and costs business year-over-year XX%. with of of INRX,XXX On INRXXX a year growth with growth was basis, India Our decline XX% full crores a a our strong
healthy we remains During the After in priority we monthly to at new and the to number eight launched rate. basis. XXXX, Indian of products the grow committed are this market a we a XX at market. India are report business continue March a IQVIA quarter, on
of and million year-over-year sequential a were of growth $XXX $XXX PCI X%. of basis, with year X%. recorded business with million sales Our X% a full the decline On of sales decline a
are there in the year, growth stopping customer back in we FY after the normalization the believe now business witness the should channel level in We in pre-COVID [indiscernible] to customer 'XX. level and During the FY steadier that 'XX. was
focus has our products, generic pipeline On the global front, value R&D a biosimilars. on asserted injectable federal building including been of
We NC are investing also few product selectively in candidates.
'XX. on While of current number in we filing the slightly accelerate been FY are this however, products the lower, track year in to has
prepared situation like we are Additionally, company, impact an performance remind to that value to have would several factors geopolitical the evolving commodity on are short-term higher assertive our moves. to and strength invest leverage which there in inorganic the balance sheet including of price. I
leaders that confident the stronger future the and approaching will ESG. strategy I be tonnage. see holding cater to and current X are Day take goals. and we for with and this, new are for I'm We our growth However, Horizon the X, goals situation every the do the floor we In emerge opportunities coming open questions will you to Investor With months, like would through Horizon for opportunities towards our readjusting in answers.
